Cantor Fitzgerald's Tracker Quants team predicts TherapeuticsMD (TXMD) will be added to the Nasdaq Biotechnology Index (IBB) on December 15 and that passive trackers will need to buy 34.5M shares of the company. This may provide additional share upside in the short term, Cantor analyst William Tanner tells investors in a research note. He reiterates an Overweight rating on TherapeuticsMD while trimming his price target for the shares to $31 from $32. The women's healthcare company closed yesterday up 23c to $5.90. Tanner continues to believe TherapeuticsMD's TX-004 will be an important new therapy for vulvar vaginal atrophy.

Jefferies analyst Maury Raycroft noted that Alnylam (ALNY) fell by over 8% on Thursday after Pfizer (PFE) announced that the phase 3 ATTR-ACT trial assessing tafamidis in TTR-CM met its primary endpoint and that Alnylam shares are trailing the iShares Nasdaq Biotechnology Index (IBB) again today. While he thinks the tafamidis data provide important clinical outcome results that support the need for treatment and benefit in TTR-CM, he also continues to believe the benefits of knocking down/depleting TTR in earlier-stage patients, as Alnylam's patisiran is meant to do, will lead to better objective improvements, Raycroft tells investors. The analyst, who recommends investors buy Alnylam amid the weakness, keeps a Buy rating on the stock.